Glucosamine Linked to 25% Increased Alzheimer’s Risk in Major Study

A new study from the University of Florida has raised alarms: the widely used joint supplement glucosamine is suspected of increasing Alzheimer’s risk. Individuals with mild cognitive impairments appear to be particularly at risk.

Study with 66,000 Patients Reveals Alarming Statistics

The analysis published in the journal Nature Metabolism is based on data from approximately 66,000 patients. The findings indicate that in individuals with existing memory issues, glucosamine elevates Alzheimer’s risk by 25%. Even more concerning, the mortality rate among diagnosed dementia patients who took glucosamine increased by 25% over a five to ten-year period.

Researchers emphasized that while a clear correlation has been identified, the exact cause remains to be confirmed through further studies.

How Glucosamine Affects the Brain

The investigation also provides explanations for the detrimental effects. In mouse models, glucosamine was shown to cross the blood-brain barrier. Once inside the brain, it triggers a process called hyperglycosylation—a dangerous increase in glycans that impairs memory, particularly social memory.

It is already known that diabetes increases the risk of Alzheimer’s by about 50%. The new findings regarding hyperglycosylation offer an additional mechanistic explanation.

Alternatives to Osteoarthritis Treatment

The efficacy of glucosamine for osteoarthritis has been a subject of controversy. Many medical organizations do not recommend the supplement due to weak clinical evidence. Alternatives for joint pain relief include non-steroidal anti-inflammatory drugs (NSAIDs).

Lifestyle as a Protective Factor

The WHO’s current guidelines from July 2026 highlight that approximately 45% of dementia risk can be modified through lifestyle factors. Experts recommend:

• Physical Activity: Walking just 3,000 steps daily can slow the spread of Alzheimer’s proteins in the brain, with better results observed at 5,000 to 7,500 steps.
• Diet: The MIND diet can lower the risk by 40%. A study published in June 2026 in JAMA Network Open also confirmed that an anti-inflammatory diet reduces dementia risk by 29%.
• Medications: SGLT2 inhibitors may reduce the risk by 43%, while GLP-1 agonists may lower it by 33%.

Advancements in Early Detection and Therapy

Alongside these warnings, positive developments are emerging. The AI model NITROGEN from Texas A&M University can predict Alzheimer’s up to seven years in advance with over 92% accuracy.

Additionally, Ruhr University Bochum published a study on July 16, 2026, in EMBO Molecular Medicine, highlighting a new blood-based marker: Amyloid-β misfolding allows for diagnosis even in asymptomatic stages, while other markers like P-tau217 accurately detect the disease only in clinical stages.

Roche is also testing the drug Trontinemab in a Phase III study called PrevenTRON to explore new treatment options for affected patient groups.